P60 Patient-reported improvements with gefapixant, a P2X3-receptor antagonist, over 52 weeks in two phase 3 clinical trials for refractory or unexplained chronic cough

Autor:	A. Martin Nguyen, Alyn H. Morice, A. Tzontcheva, Jacky Smith, Peter V. Dicpinigaitis, S S Birring, Lorcan McGarvey, I D Pavord, Qing Li, Jonathan Schelfhout, David Muccino, C. La Rosa
Rok vydání:	2021
Předmět:	Clinical trial medicine.medical_specialty Chronic cough Refractory business.industry Internal medicine Antagonist medicine medicine.symptom business Gastroenterology P2X3 Receptor
Zdroj:	Cough: is it a problem and what can we do about it?.
DOI:	10.1136/thorax-2021-btsabstracts.170
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b69912dcbc2fc959bafe4ae0eb6b3fab https://doi.org/10.1136/thorax-2021-btsabstracts.170 Zobrazit plný text záznamu